Treatment of Anemia with Darbepoetin Alfa in Patients with Low and Intermediate-1 Risk Myelodysplastic Syndromes. Results from the ARAMYS Study

被引：1
|
作者：
Villegas, Ana [1 ]
Arrizabalaga, B. [2 ]
Fernandez-lago, C. [3 ]
Mouzo, M. [4 ]
Mayans, Jr [5 ]
Gonalez-Porras, Jr [6 ]
Duarte, Rafael [7 ]
Remacha, Angel Francisco [8 ]
Luno, Elisa [9 ]
Gasquet, J. A.
机构：
[1] Hosp Clin San Carlos, Madrid, Spain
[2] Hosp Cruces, Dept Haematol, Bilbao, Spain
[3] Hosp Juan Canalejo, Dept Haematol, La Coruna, Spain
[4] Complejo HU Vigo Xeral Cies, Dept Haematol, Vigo, Spain
[5] Hosp Arnau Vilanova, Dept Haematol, Valencia, Spain
[6] Hosp Univ Salamanca, Salamanca, Spain
[7] Hosp Duran & Reynals ICO, Bellvitge, Spain
[8] Hosp Santa Creu & Sant Pau, Barcelona, Spain
[9] Hosp Univ Cent Asturias, Oviedo, Spain
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
10.1182/blood.V112.11.3451.3451
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1184 / 1184
页数：1
相关论文
共 50 条
  • [21] 5-AZACYTIDINE FOR THE TREATMENT OF LOW/INTERMEDIATE-1 IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS IN 63 PATIENTS FROM THE ITALIAN PATIENT NAMED PROGRAM
    Musto, P.
    Maurillo, L.
    Spagnoli, A.
    Gozzini, A.
    Rivellini, F.
    Tatarelli, C.
    Lunghi, M.
    Fili, C.
    Orciuolo, E.
    Ciuffreda, L.
    Vigna, E.
    Della Cioppa, P.
    Ferrero, D.
    Palmieri, S.
    Palumbo, G.
    Di Renzo, N.
    Oliva, E.
    Sanpaolo, G.
    Pastore, D.
    Tonso, A.
    Santagostino, A.
    Villani, O.
    D'Auria, F.
    D'Arco, A.
    Gaidano, G.
    Galimberti, S.
    Russo, D.
    Venditti, A.
    Aloe-Spiriti, M. A.
    Leone, G.
    Santini, V.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 368 - 368
  • [22] Antithymocyte globulin for the treatment of patients with 'low risk' myelodysplastic syndromes.
    Killick, S
    Marsh, JCW
    Cavenagh, J
    Mijovic, A
    Mufti, G
    Gordon-Smith, EC
    Bowen, D
    BRITISH JOURNAL OF HAEMATOLOGY, 1999, 105 : 69 - 69
  • [23] Antithymocyte globulin for the treatment of patients with 'low risk' myelodysplastic syndromes.
    Killick, SB
    Marsh, JC
    Cavenagh, JD
    Mijovic, A
    Mufti, G
    Gordon-Smith, EC
    Bowen, DT
    BLOOD, 1999, 94 (10) : 306A - 307A
  • [24] Darbepoetin alfa for treating anemia in patients with low-risk myelodysplastic syndromes: Exploratory analysis of baseline predictors of response.
    Gabrilove, J.
    Paquette, R.
    Lyons, R.
    Mushtaq, C.
    Sekeres, M.
    Lam, H.
    Dreiling, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 356S - 356S
  • [25] ACE-536 INCREASES HEMOGLOBIN LEVELS IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM A PHASE 2 STUDY
    Platzbecker, U.
    Germing, U.
    Giagounidis, A.
    Goetze, K.
    Kiewe, P.
    Mayer, K.
    Ottmann, O.
    Radsak, M.
    Wolff, T.
    Hankin, M.
    Wilson, D.
    Sherman, M.
    Attie, K.
    HAEMATOLOGICA, 2014, 99 : 500 - 500
  • [26] LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM A PHASE 2 STUDY
    Platzbecker, U.
    Germing, U.
    Giagounidis, A.
    Goetze, K.
    Kiewe, P.
    Mayer, K.
    Ottmann, O.
    Radsak, M.
    Wolff, T.
    Haase, D.
    Hankin, M.
    Wilson, D.
    Zhang, X.
    Laadem, A.
    Sherman, M.
    Attie, K.
    LEUKEMIA RESEARCH, 2015, 39 : S25 - S25
  • [27] EFFECT OF ERYTROPOIETIN-ALFA IN LOW AND INTERMEDIATE 1 RISK MYELODYSPLASTIC SYNDROMES WITH ANEMIA: ONE CENTER EXPERIENCE
    Ertop, S.
    Aslaner, M.
    Erol, B.
    Ilikhan, S.
    Bilici, M.
    LEUKEMIA RESEARCH, 2015, 39 : SS21 - SS21
  • [28] Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality
    Hironori Harada
    Mitsumasa Watanabe
    Kenshi Suzuki
    Soshi Yanagita
    Takahiro Suzuki
    Yataro Yoshida
    Akiro Kimura
    Mitsuru Tsudo
    Akira Matsuda
    Kaoru Tohyama
    Masafumi Taniwaki
    Kenichi Takeshita
    Masaaki Takatoku
    Keiya Ozawa
    International Journal of Hematology, 2009, 90 : 353 - 360
  • [29] Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality
    Harada, Hironori
    Watanabe, Mitsumasa
    Suzuki, Kenshi
    Yanagita, Soshi
    Suzuki, Takahiro
    Yoshida, Yataro
    Kimura, Akiro
    Tsudo, Mitsuru
    Matsuda, Akira
    Tohyama, Kaoru
    Taniwaki, Masafumi
    Takeshita, Kenichi
    Takatoku, Masaaki
    Ozawa, Keiya
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 90 (03) : 353 - 360
  • [30] Randomized Open-Label Phase II Study of Decitabine in Patients with Low- or Intermediate-1 Risk Myelodysplastic Syndromes
    Garcia-Manero, Guillermo
    Jabbour, Elias
    Borthakur, Gautam
    Faderl, Stefan
    Estrov, Zeev
    Godley, Lucy
    Gabrail, Nashat Y.
    Berdeja, Jesus G.
    Nadeem, Ahmed
    Stein, Karen
    Noble, Yvonne
    Kassalow, Laurent
    Kantarjian, Hagop M.
    BLOOD, 2011, 118 (21) : 1628 - 1629
12345